BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 22, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Elpiscience's anti-CD39 x TGF-β bispecific antibody ES-014 cleared for phase I study in solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Elpiscience's anti-CD39 x TGF-β bispecific antibody ES-014 cleared for phase I study in solid tumors
Dec. 23, 2022
No Comments
Elpiscience Biopharmaceuticals Inc. has announced Center of Drug Evaluation (CDE) clearance of its IND application for ES-014 for a phase I study in patients with advanced solid tumors.
BioWorld Science
Cancer
Bispecific antibody
Immuno-oncology
IND
